Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(12):1091–1098. doi: 10.1111/j.1349-7006.2003.tb01405.x

Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK‐432 combined with prostaglandin E2

Marimo Sato 1, Takuya Takayama 1, Hiroaki Tanaka 1, Juichiro Konishi 1, Toshihiro Suzuki 1, Teruo Kaiga 1, Hideaki Tahara 1,✉
PMCID: PMC11160059  PMID: 14662025

Abstract

Dendritic cell (DC) administration appears to be a very promising approach for the immunotherapy of cancer. The results of clinical studies have suggested that the nature and the magnitude of antitumor immune responses are critically affected by DC functions, including production of T helper type 1 (Th1)‐inducing cytokines, activation of T cell subsets and natural killer (NK) cells, and migration from peripheral tissues to the T cell area of the draining lymph nodes. Administration of immature DCs could fail to fully stimulate antigen‐specific immune responses and might induce tolerance under some conditions. In this study, we developed a method to obtain fully mature DCs, and we compared in detail the DCs thus obtained with those obtained using a maturation stimulus termed monocyte‐derived medium (MCM)‐mimic, which is a mixture of recombinant cytokines and prostaglandin E2 (PGE2) mimicking the components of monocyte‐conditioned medium. Using DCs derived from monocytes of advanced cancer patients in this study, we found that DCs stimulated with OK‐432 alone showed phenotypes similar to those of mature DCs induced using MCM‐mimic, though with better secretion of IL‐6 and IL‐12. However, these DCs were found to have poor migratory capacity associated with the marginal expression of CCR7. When OK‐432 was combined with PGE2, the CCR7 expression and migratory capacity of DCs were significantly improved without impairing other immuno‐stimulatory functions. These results suggest that stimulation with the combination of OK‐432 and PGE2 could be applicable as an alternative to MCM‐mimic in clinical trials which require fully matured DCs to induce Th1‐type immune responses against tumor cells even in patients with advanced cancer.

References

  • 1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52. [DOI] [PubMed] [Google Scholar]
  • 2. Palucka K, Banchereau J. Dendritic cells: a link between innate and adaptive immunity. J Clin Immunol 1999; 19: 12–25. [DOI] [PubMed] [Google Scholar]
  • 3. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. The natural killer T (NKT) cell ligand α‐galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)‐12 production by dendritic cells and IL‐12 receptor expresion on NKT cells. J Exp Med 1999; 189: 1121–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Ridge JP, Rosa FD, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T‐helper and a T‐killer cell. Nature 1998; 393: 474–8. [DOI] [PubMed] [Google Scholar]
  • 5. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 95: 459–73. [DOI] [PubMed] [Google Scholar]
  • 6. Thuener B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuleret G. Vaccination with MAGE‐3A1 peptide‐pulsed mature, monocytes‐derived dendritic cells expands specific cytotoxic T calls and induces regression of some metastasis in advanced stage IV melanoma. J Exp Med 1999; 190: 1669–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Lee K, Wang E, Nielsen M, Wunderrilich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine‐specific T cell frequency after peptide‐based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292–300. [PubMed] [Google Scholar]
  • 8. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245–73. [DOI] [PubMed] [Google Scholar]
  • 9. Bennett SR, Carbone FR, Karamalis F, Fravell RA, Miller JFAP, Heath WR. Help for cytotoxic T cell responses is mediated by CD40 signaling. Nature 1998; 393: 478–80. [DOI] [PubMed] [Google Scholar]
  • 10. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T cell help for cytotoxic T lymphocytes is mediated by CD40‐CD40L interactions. Nature 1998; 393: 480–3. [DOI] [PubMed] [Google Scholar]
  • 11. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double‐stranded RNA. J Exp Med 1999; 182: 821–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W. A controlled clinical trial with a specifically configured RNA drug, poly(I):poly(C) 12 U, in chronic fatigue syndrome. Clin Infect Dis 1994; 18: S88–95. [DOI] [PubMed] [Google Scholar]
  • 13. Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N. A monocytes conditioned medium is more effective than defined cytokines mediating the terminal maturation of human dendritic cells. Blood 1997; 90: 3640–6. [PubMed] [Google Scholar]
  • 14. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immuno‐stimulatory dendritic cells under fetal calf serum‐free conditions. Eur J Immunol 1997; 27: 3135–42. [DOI] [PubMed] [Google Scholar]
  • 15. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK‐432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 2003; 63: 4112–8. [PubMed] [Google Scholar]
  • 16. Okamoto H, Shin J, Mion S, Koshimura S, Shimizu R. Studies on the anti‐cancer and streptolysin S‐forming abilities of hemolytic streptococci. Jpn J Microbiol 1967; 11: 323–36. [DOI] [PubMed] [Google Scholar]
  • 17. Thurner B, Roder C, Dickmann D, Heuer M, Kruse M, Slaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical apprication. J Immunol Methods 1999; 223: 1–15. [DOI] [PubMed] [Google Scholar]
  • 18. Feuerstein B, Berger TG, Maczek C, Roder C, Schreiner D, Hirsch U, Haendle I, Leisgang W, Glaser A, Kuss O, Diegen TL, Schuler G, Schuler‐Thurner B. A method for the production of cryopreserved aliquots of antigen‐preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000; 245: 15–29. [DOI] [PubMed] [Google Scholar]
  • 19. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibi B, Niederwieser D, Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137–51. [DOI] [PubMed] [Google Scholar]
  • 20. Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, Lotze MT, Tahara H. CC chemokine receptor‐7 on dendritic cells is induced after interaction with apoptopic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000; 60: 2209–17. [PubMed] [Google Scholar]
  • 21. Luft T, Jefford M, Luetjens P, Toy T, Hochrei H, Masterman KA, Maliszewski C, Shortman K, Cebon J, Maraskovsky E. Functional distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 2002; 100: 1362–72. [DOI] [PubMed] [Google Scholar]
  • 22. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Pristaglandin E2 is a key factor CCR7 surface expression and migration of monocytes‐derived dendritic cells. Blood 2002; 100: 1354–61. [DOI] [PubMed] [Google Scholar]
  • 23. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell‐based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 829–33. [PubMed] [Google Scholar]
  • 24. Murphy GP, Tojoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: a phase 2 prostate cancer vaccine trail involving patients with hormone‐refractory metastatic disease. Prostate 1999; 38: 73–8. [DOI] [PubMed] [Google Scholar]
  • 25. Dhodapkar MV, Steinmen RM, Krasovsky J, Munz M, Bhardwaj N. Antigen‐specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Toyokawa H, Inaba M, Takai S, Satoi S, Beuth J, Ko HL, Matsui Y, Kwon AH, Kamiyama Y, Ikehara S. Enhancement of circulating dendritic cell activity by immunomodulators (OK‐432 and KP‐40). Anticancer Res 2002; 22: 2137–45. [PubMed] [Google Scholar]
  • 27. Pasare C, Medzhitov R. Toll pathway‐dependent blockade of CD4+ CD25+ T cell‐mediated suppression by dendritic cells. Science 2003; 299: 1033–6. [DOI] [PubMed] [Google Scholar]
  • 28. Forster R, Schubel A, Brerifeld D, Kremmer E, Renner‐Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 23–33. [DOI] [PubMed] [Google Scholar]
  • 29. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999; 189: 447–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait‐Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic site. J Exp Med 1998; 188: 373–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Sallusto F, Palermo B, Lenig D, Mittinen M, Matikainen S, Julkunen I, Forster R, Burgstahler R, Lipp M, Lanzavecchia A. Distinct pattern and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999; 29: 1617–25. [DOI] [PubMed] [Google Scholar]
  • 32. Yanagihara S, Komura E, Nagafue J, Watarai H, Yamaguchi Y. ERI1/CCR7 is new member of dendritic cell chemokine receptor that is up‐regulated upon maturation. J Immunol 1998; 161: 3096–102. [PubMed] [Google Scholar]
  • 33. Kalinski P, Vieria PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E2 is a selective inducer of interleukin‐12p40 (IL‐12p40) production and an inhibitor of bioactive IL‐12p70 heterodimer. Blood 2001; 97: 3446–49. [DOI] [PubMed] [Google Scholar]
  • 34. Steinbrink K, Paragnik L, Jonuleit H, Tuting T, Knop J, Enk AH. Induction of dendritic cell maturation and modulation of dendritic cell‐induced immune responses by prostaglandins. Arch Dermatol Res 2000; 292: 437–45. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES